AzurRx BioPharma, Inc. - FORM 10-K - EX-32 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - March 31, 2021

Attached files

file filename
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - AzurRx BioPharma, Inc.ex31-1.htm
EX-23 - CONSENTS OF EXPERTS AND COUNSEL - AzurRx BioPharma, Inc.ex23-1.htm
EX-4 - EXHIBIT 4.19 - AzurRx BioPharma, Inc.ex4-19.htm
10-K - ANNUAL REPORT - AzurRx BioPharma, Inc.azrx10k_dec312020.htm
 
Exhibit 32.1
 
CERTIFICATION PURSUANT TO 
18 U.S.C. SECTION 1350, 
AS ADOPTED PURSUANT TO 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
   
In connection with the Annual Report of AzurRx BioPharma, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Sapirstein, Chief Executive Officer of the Company, and Daniel Schneiderman, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
  
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 

Date: March 31, 2021
/s/ James Sapirstein
 
James Sapirstein
President and Chief Executive Officer
(Principal Executive Officer)
 
 
 
 
 
/s/ Daniel Schneiderman
Daniel Schneiderman
Chief Financial Officer
(Principal Financial and Accounting Officer)
 
 
 
 
 
 
 
 
 

AzurRx BioPharma, Inc. Reports